Erasca Inc stock (US29479V1044): Q1 2026 loss and Nasdaq price move in focus

Erasca shares on the Nasdaq in the United States remain in focus after the clinical-stage oncology company reported a wider Q1 2026 net loss in May and continues to trade actively ahead of its next expected earnings date.

Erasca Inc shares on the Nasdaq in the United States remain in focus after the clinical-stage oncology company reported a wider net loss for Q1 2026 in May, while the stock continues to trade actively ahead of its next expected earnings update based on the company’s usual reporting pattern, according to Nasdaq data and company filings as of 05/11/2026.

The stock trades on Nasdaq in USD under the ticker ERAS, anchoring Erasca firmly in the U.S. biotechnology and healthcare equity universe, with investors paying close attention to both its clinical milestones and cash burn as management advances a pipeline of precision oncology candidates.

As of: 02/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Erasca Inc
• Sector/industry: Biotechnology - oncology-focused clinical-stage therapeutics
• Headquarters/country: San Diego, United States
• Core markets: United States and global oncology trial centers
• Key revenue drivers: Collaboration income and milestone payments, with longer-term potential from targeted cancer therapies if approved
• Home exchange/listing venue: Nasdaq (ERAS)
• Trading currency: USD

Erasca Inc: core business model

Erasca Inc pursues a focused biotechnology model that centers on discovering and clinically developing precision oncology drug candidates aimed at specific cancer-driving alterations, with potential future revenues expected to stem primarily from commercializing these therapies and forming strategic collaborations once key assets reach later-stage development.

Latest quarterly results for Erasca Inc at a glance

For Q1 2026, Erasca reported a net loss per share of USD -0.60 in a filing dated 05/11/2026, compared with the analysts’ consensus estimate of around USD -0.12 per share compiled by MarketBeat for the same period, highlighting a materially wider loss than anticipated by the market. According to the same MarketBeat summary as of 05/11/2026, the company’s reported Q1 2026 result therefore missed the consensus by approximately USD 0.49 per share, underlining how research and development investment and operating expenses continue to weigh on near-term earnings while the pipeline remains largely in the clinical stage.

MarketBeat also indicates that Erasca’s next earnings date is estimated for 08/11/2026 based on its historical reporting calendar, although the company itself has not yet confirmed this timing in a formal release, meaning investors use this provisional date as a planning reference rather than a fixed guidance point. With the stock trading on the Nasdaq in the United States and reflecting sentiment on both trial progress and funding visibility, each quarterly update on operating expenses, cash runway and clinical milestones is closely followed by market participants monitoring the balance between pipeline advancement and dilution risk.

Conclusion

Erasca Inc’s latest reported quarter shows a Q1 2026 net loss per share of USD -0.60 that was significantly wider than the consensus estimate compiled by MarketBeat, keeping attention on the company’s spending profile and cash position as it advances its oncology pipeline. With the next earnings release still only estimated rather than formally scheduled, the stock’s Nasdaq performance in the United States will likely continue to be guided by expectations around trial progress, financing options and how future quarterly numbers align with market forecasts.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.